Your browser is no longer supported. Please, upgrade your browser.
HCM Hutchison China MediTech Limited daily Stock Chart
HCM [NASD]
Hutchison China MediTech Limited
Index- P/E- EPS (ttm)-0.70 Insider Own6.58% Shs Outstand138.12M Perf Week-11.63%
Market Cap3.45B Forward P/E- EPS next Y-1.05 Insider Trans0.00% Shs Float54.77M Perf Month8.04%
Income- PEG- EPS next Q-0.13 Inst Own30.59% Short Float3.03% Perf Quarter5.89%
Sales204.65M P/S16.87 EPS this Y-63.20% Inst Trans- Short Ratio6.72 Perf Half Y21.77%
Book/sh2.36 P/B10.62 EPS next Y-12.90% ROA- Target Price33.83 Perf Year-3.88%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range16.47 - 32.55 Perf YTD-0.28%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-25.31% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low47.60% ATR1.26
Employees714 Current Ratio- Sales Q/Q-16.10% Oper. Margin- RSI (14)37.76 Volatility5.00% 4.24%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.25 Prev Close25.00
ShortableYes LT Debt/Eq- EarningsMar 03 BMO Payout- Avg Volume246.46K Price24.31
Recom1.70 SMA20-7.35% SMA50-6.25% SMA2004.26% Volume42,511 Change-2.76%
Feb-20-20Initiated Goldman Buy
Nov-19-19Initiated CLSA Buy
Oct-23-19Reiterated BofA/Merrill Buy $35 → $29
Jul-05-19Initiated Macquarie Outperform
Feb-25-20 02:15AM  Chi-Med to announce 2019 Final Results on Tuesday, March 3, 2020 adjustment to announcement and presentation logistics due to travel restrictions GlobeNewswire
Feb-12-20 08:00PM  RPT-FOCUS-Coronavirus outbreak begins to disrupt booming China drug trials Reuters
12:27PM  FOCUS-Coronavirus outbreak begins to disrupt booming China drug trials Reuters
Feb-10-20 05:08AM  Chi-Med Highlights Updated Phase II Savolitinib / Imfinzi® Combination Data in Advanced Papillary Renal Cell Carcinoma at 2020 ASCO Genitourinary Cancers Symposium GlobeNewswire
Feb-06-20 02:58AM  Chi-Med Announces the Exercise of Underwriters Over-allotment Option for Public Offering of ADSs GlobeNewswire
Jan-31-20 02:19AM  Chi-Med to Announce 2019 Final Results GlobeNewswire
Jan-23-20 11:52PM  Hutchison China MediTech Limited Just Released Its Third-Quarter Earnings: Here's What Analysts Think Simply Wall St. -9.93%
03:06AM  Chi-Med Announces Pricing of US$110 Million Public Offering of ADSs GlobeNewswire
Jan-21-20 06:46PM  Chi-Med Announces Proposed Public Offering of ADSs GlobeNewswire
08:00AM  Moving Average Crossover Alert: Hutchison China MediTech Zacks
Jan-20-20 06:17AM  Will Hutchison China MediTech Continue to Surge Higher? Zacks
06:08AM  Chi-Med Announces that Surufatinib Phase III SANET-p Study Has Already Achieved its Primary Endpoint in Advanced Pancreatic Neuroendocrine Tumors in China and Will Stop Early GlobeNewswire
Jan-16-20 12:00PM  Hutchison China MediTech (HCM) Is Up 0.6% in One Week: What You Should Know Zacks
Jan-13-20 02:00AM  Chi-Med Initiates a Phase II Trial of Surufatinib in Combination with Tuoyi in Patients with Advanced Solid Tumors GlobeNewswire
Jan-06-20 02:50AM  Chi-Med to Present at the 38th Annual JP Morgan Healthcare Conference GlobeNewswire
Dec-20-19 02:05AM  Chi-Meds New Drug Application for Surufatinib in Non-Pancreatic Neuroendocrine Tumors Granted Priority Review in China GlobeNewswire
Dec-14-19 06:39PM  Hedge Funds Arent Crazy About Hutchison China MediTech Limited (HCM) Anymore Insider Monkey
Dec-09-19 06:16AM  Highlights From The Deutsche Bank ADR Virtual Investor Conference Benzinga
Nov-29-19 07:35AM  Edison issues ADR update on Hutchison China MediTech (HCM) ACCESSWIRE
Nov-28-19 02:15AM  Chi-Meds Elunate® (Fruquintinib Capsules) Included in the National Reimbursement Drug List in China GlobeNewswire
Nov-25-19 02:15AM  Chi-Med Announces Surufatinib Granted FDA Orphan Drug Designation for Pancreatic Neuroendocrine Tumors GlobeNewswire
Nov-22-19 08:00PM  Chi-Med Highlights Oral Presentations at 2019 ESMO Asia Annual Meeting GlobeNewswire
Nov-15-19 08:35AM  Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for On-Demand Viewing PR Newswire
01:01AM  How Much Of Hutchison China MediTech Limited (LON:HCM) Do Institutions Own? Simply Wall St.
Nov-11-19 02:15AM  Chi-Med Announces NDA Acceptance in China for Surufatinib in Non-Pancreatic Neuroendocrine Tumors GlobeNewswire
Nov-06-19 08:35AM  International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 13th and 14th, 2019 PR Newswire
08:35AM  International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 13th and 14th, 2019 CNW Group
Oct-29-19 01:58PM  Hedge Funds Have Never Been This Bullish On Hutchison China MediTech Limited (HCM) Insider Monkey
Oct-17-19 02:45AM  Chi-Med highlights publication of Phase II data showing promising efficacy for Savolitinib in MET-amplified gastric cancers GlobeNewswire
Oct-10-19 07:45AM  Edison issues ADR update on Hutchison China MediTech (HCM) ACCESSWIRE
04:15AM  Innovent and Chi-Med Expand Global Collaboration to Evaluate the Combination of Sintilimab and Surufatinib in Solid Tumors GlobeNewswire
Oct-04-19 02:39AM  Chi-Med Initiates an International Phase I/Ib Trial of HMPL-523 in Patients with Advanced Relapsed or Refractory Lymphoma GlobeNewswire
Oct-01-19 03:35AM  Investors Who Bought Hutchison China MediTech (LON:HCM) Shares Five Years Ago Are Now Up 152% Simply Wall St.
Sep-30-19 09:12AM  CK Hutchison prices offering of Chi-Med share capital enabling deconsolidation and confirms its intention to hold Chi-Med as a strategic investment for the long term GlobeNewswire
09:10AM  Hutchison China MediTech Solutions Enters Oversold Territory Zacks
07:16AM  CK Hutchison offers 1.3% of Chi-Meds share capital aiming to deconsolidate and hold Chi-Med as a strategic investment for the long term GlobeNewswire
Sep-29-19 11:00AM  Chi-Med to Discuss Surufatinib Phase III and U.S. Phase I/Ib Efficacy and Safety Data Presented at the 2019 ESMO Annual Meeting GlobeNewswire
Sep-25-19 02:15AM  Chi-Med Highlights Presentation of Clinical Data from the Successful SANET-ep Phase III Trial at ESMO Annual Meeting GlobeNewswire
Sep-18-19 02:15AM  Chi-Med Highlights Oral Presentations at 2019 CSCO Annual Meeting GlobeNewswire
Sep-16-19 09:39AM  Top Ranked Momentum Stocks to Buy for September 16th Zacks -6.02%
Sep-03-19 02:46AM  Chi-Med to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference GlobeNewswire -5.32%
02:25AM  Chi-Med Initiates an International Phase I/Ib Trial of HMPL-689 in Patients with Advanced Relapsed or Refractory Lymphoma GlobeNewswire
Aug-26-19 12:54AM  Does Hutchison China MediTech Limited's (LON:HCM) CEO Pay Compare Well With Peers? Simply Wall St.
Aug-23-19 02:15AM  Chi-Med Initiates a Phase I Trial of HMPL-523 in Patients with Immune Thrombocytopenia (ITP) in China GlobeNewswire
Aug-14-19 10:15AM  Edison issues ADR update on Hutchison China MediTech (HCM) ACCESSWIRE
Jul-30-19 02:41PM  Hutchison China MediTech Limited (HCM) Q2 2019 Earnings Call Transcript Motley Fool
04:43AM  Chi-Med Reports 2019 Interim Results and Provides Updates on Key Clinical Programs GlobeNewswire
Jul-19-19 03:16PM  Credit Suisse initiates coverage of AMC with optimistic outlook Yahoo Finance Video
Jul-17-19 08:38AM  FACTORIAL MANAGEMENT Ltd Buys Hutchison China Meditech GuruFocus.com
Jul-05-19 09:55AM  Edison Issues ADR Outlook on Hutchison China MediTech (HCM) ACCESSWIRE
Jul-03-19 02:00AM  Chi-Med to Announce 2019 Half-Year Financial Results GlobeNewswire
Jun-28-19 11:50AM  Why Chi-Med Stock Is Tanking Today Motley Fool -27.15%
05:33AM  Chi-Med Announces Pricing of Upsized U.S. Public Secondary Offering of American Depositary Shares GlobeNewswire
Jun-27-19 05:37PM  Chi-Med Announces Secondary Offering of American Depositary Shares GlobeNewswire
Jun-18-19 01:56AM  Li Ka Shing-Backed Cancer Drug Developer Delays Launch of Hong Kong Listing Bloomberg +6.52%
Jun-14-19 04:00AM  Chi-Med Announces that Surufatinib Phase III SANET-ep Study Has Met its Primary Endpoint at Interim Analysis in Advanced Non-Pancreatic Neuroendocrine Tumors in China and Will Stop Early GlobeNewswire
May-17-19 08:35AM  Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for On-Demand Viewing PR Newswire
May-10-19 12:00PM  International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on May 15th and 16th, 2019 CNW Group
Apr-26-19 11:52AM  Did Hedge Funds Drop The Ball On Hutchison China MediTech Limited (HCM) ? Insider Monkey
Apr-15-19 09:36AM  Biotech group Chi-Med plans Hong Kong listing of up to $500 mln - sources Reuters
02:23AM  Chi-Med Files Application to List in Hong Kong and Announces Proposed Global Offering GlobeNewswire
Apr-01-19 04:54AM  Chi-Med CEO: I don't lose sleep over IP concerns in China CNBC Videos
Mar-29-19 03:00AM  Chi-Med Initiates a Phase IIb/III Trial of Surufatinib in Patients with Unresectable or Metastatic Biliary Tract Cancer in China GlobeNewswire
Mar-28-19 03:30AM  Chi-Med Highlights Oral Presentations on Savolitinib Lung Cancer Programs at AACR Annual Meeting GlobeNewswire
Mar-11-19 02:00AM  Chi-Med Reports 2018 Full Year Results and Provides Updates on Key Clinical Programs GlobeNewswire
Feb-12-19 02:18AM  Chi-Med Highlights Preliminary Phase II Savolitinib / Imfinzi® Combination Data in Advanced Papillary Renal Cell Carcinoma at 2019 ASCO Genitourinary Cancers Symposium GlobeNewswire +5.10%
Feb-08-19 02:34AM  Chi-Med to Announce 2018 Final Results GlobeNewswire
Jan-07-19 02:00AM  Chi-Med to Present at the 37th Annual JP Morgan Healthcare Conference GlobeNewswire
Dec-20-18 02:28AM  Chi-Med Announces Progress in Savolitinib Lung Cancer Program and Update on Kidney Cancer Strategy GlobeNewswire -10.58%
02:00AM  Chi-Med Announces Amendment to the 2013 License & Collaboration Agreement on Fruquintinib with Eli Lilly and Company GlobeNewswire
Nov-29-18 10:10AM  BRIEF-Innovent Biologics Enters Global Collaboration Agreement With Hutchison China Meditech Reuters
03:00AM  Chi-Med Enters into Multiple Collaborations to Evaluate Combinations of Surufatinib and Fruquintinib with PD-1 Checkpoint Inhibitors GlobeNewswire
Nov-26-18 02:00AM  Chi-Med Announces First Commercial Launch of Fruquintinib Capsules (Elunate®) GlobeNewswire +5.19%
Nov-16-18 02:00AM  Chi-Med Announces Phase III FALUCA Trial Results for Fruquintinib in Third-Line, Advanced Non-Small Cell Lung Cancer in China GlobeNewswire -17.60%
Oct-18-18 02:00AM  Chi-Med Initiates a Phase I Trial of HMPL-523 in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia in China GlobeNewswire
Sep-05-18 03:27AM  Boost for "made in China" medicine as Chi-Med wins key approval Reuters
02:00AM  Chi-Med Announces the Approval of Fruquintinib Capsules for Previously Treated Colorectal Cancer in China GlobeNewswire
Aug-22-18 10:06AM  Hutchison China Meditech CEO Emphasizes Seizing Opportunities Bloomberg
Jul-27-18 02:00PM  Hutchison China MediTech Limited Sponsored ADR to Host Earnings Call ACCESSWIRE
02:00AM  Chi-Med Reports 2018 Interim Results and Updates Shareholders on Key Clinical Programs GlobeNewswire
Jul-23-18 02:00AM  Chi-Med Initiates a Phase Ib/II Proof-of-Concept Trial of Sulfatinib in Pancreatic Neuroendocrine Tumors and Biliary Tract Cancer in the United States GlobeNewswire
Jun-29-18 02:00AM  Chi-Med to Announce 2018 Half-Year Financial Results GlobeNewswire
Jun-04-18 04:51AM  Chi-Med Presents Further Fruquintinib FRESCO Trial Data at ASCO 2018 Annual Meeting GlobeNewswire
May-18-18 11:27AM  Is Hutchison China MediTech Limited (LON:HCM) Expensive For A Reason? A Look At The Intrinsic Value Simply Wall St.
May-11-18 07:34AM  Chi-Med to Present at Bank of America Merrill Lynch Annual Health Care Conference GlobeNewswire
Mar-16-18 08:35AM  International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on March 21st and 22nd, 2018 PR Newswire
Mar-12-18 04:01AM  Chi-Med Reports Final Results for the Year Ended December 31, 2017 and Updates Shareholders on Key Clinical Programs Business Wire
Mar-06-18 10:35AM  Is Hutchison China MediTech Limiteds (NASDAQ:HCM) Liquidity As Good As Its Solvency? Simply Wall St.
02:00AM  Chi-Med Initiates a Phase Ib/II Proof-of-Concept Trial of Epitinib in Glioblastoma in China Business Wire
Feb-14-18 06:02AM  Financially Sounds Stocks Poised For High Growth Simply Wall St.
Feb-13-18 02:00AM  Chi-Med Completes Enrollment of 527 Patients in Pivotal Phase III FALUCA Trial with Fruquintinib in Lung Cancer Business Wire
Jan-01-18 11:39AM  ETFs with exposure to Hutchison China MediTech Ltd. : January 1, 2018 Capital Cube
Dec-19-17 01:12PM  ETFs with exposure to Hutchison China MediTech Ltd. : December 19, 2017 Capital Cube
Dec-15-17 02:00AM  Chi-Med Initiates Fruquintinib U.S. Clinical Trials Business Wire
Nov-18-17 01:44PM  What You Must Know About Hutchison China MediTech Limiteds (HCM) Return on Equity Simply Wall St.
Oct-31-17 03:20AM  Chi-Med Initiates FRUTIGA, a Phase III Trial of Fruquintinib in Second-Line Gastric Cancer Business Wire
Oct-30-17 11:45AM  Chi-Med Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately US$301.3 Million on the Nasdaq Global Select Market Business Wire
Oct-27-17 07:26AM  Chi-Med Announces the Full Exercise of Underwriters' Over-allotment Option Business Wire
Oct-25-17 11:56PM  Chi-Med Announces Pricing of U.S. Public Offering of ADSs Raising US$262 Million on Nasdaq Global Select Market Business Wire
02:42AM  China cancer specialist Chi-Med plans $262 mln share offering Reuters
Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China and Hong Kong. The company operates through Innovation Platform and Commercial Platform segments. The company discovers and develops therapeutics in oncology and autoimmune diseases, as well as provides research and development services; and develops, manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. Its clinical stage drugs include Savolitinib, a c-MET inhibitor for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma, colorectal cancer, gastric cancer, and prostate cancer; and Fruquintinib, a inhibitor for the treatment of colorectal cancer and solid tumors. The company is also developing Surufatinib, an inhibitor for the treatment of pancreatic neuroendocrine tumors and solid tumors; and HMPL-523, an inhibitor for the treatment of indolent non-Hodgkin's lymphoma, as well as HMPL-689, a treatment for indolent non-Hodgkin's lymphoma and healthy volunteers. The company was incorporated in 2000 and is headquartered in Central, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.